Follitropin-α (Gonal-F) versus follitropin-β (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any difference?

Fertility and Sterility

Volumn 91, Issue 4 SUPPL., 2009, Pages 1522-1525

  Orvieto, Raoul ^a   Nahum, Ravit ^a   Rabinson, Jacob ^a   Ashkenazi, Jacob ^b   Anteby, Eyal Y ^a   Meltcer, Simion ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; GENERIC DRUG; GONADORELIN ANTAGONIST; GONADOTROPIN; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FERTILIZATION IN VITRO; HORMONE BLOOD LEVEL; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; PREGNANCY RATE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; ESTROGENS; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; FOLLICLE STIMULATING HORMONE, BETA SUBUNIT; GLYCOPROTEIN HORMONES, ALPHA SUBUNIT; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY, FEMALE; OOCYTE RETRIEVAL; OVULATION INDUCTION; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY RATE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 63449106868     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.08.112     Document Type: Article

References (19)

1. Penzias A.S. Improving results with assisted reproductive technologies: individualized patient-tailored strategies for ovulation induction. Reprod Biomed Online 9 (2004) 43-46
2. Galway A.B., Hsueh A.J., Keene J.L., Yamoto M., Fauser B.C., and Boime I. In vitro and in vivo bioactivity of recombinant human follicle-stimulating hormone and partially deglycosylated variants secreted by transfected eukaryotic cell lines. Endocrinology 127 (1990) 93-100
3. ®). Mol Hum Reprod 5 (1996) 361-369
4. Out H.J., Driessen S.G., and Mannaerts B.M. Coelingh Bennink HJ. Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins. Fertil Steril 68 (1997) 138-142
5. Bergh C., Howles C., Borg K., Hamberger L., Josefsson B., Nilsson L., et al. Recombinant human follicle stimulating hormone (r-hFSH, Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques. Hum Reprod 12 (1997) 2133-2139
6. Manassiev N.S., Tenekedjier K.I., and Collins J. Does the use of recombinant follicle-stimulating hormone lead to higher pregnancy rates in in vitro fertilisation-embryo transfer cycles?. Assist Reprod 9 (1999) 7-12
7. Frydman R., Howles C.M., and Truon G. A double blind, randomised study to compare recombinant human follicle stimulating hormone (FSH: Gonal-F) with highly purified FSH (Metrodin-HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. Hum Reprod 15 (2000) 520-525
8. Daya S., Gunby J., Hughes E.G., Collins J.A., and Sagle M.A. Follicle stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis. Fertil Steril 64 (1995) 347-354
9. Van Wely M., Westergaard L.G., Bossuyt P.M., and Van der Veen F. Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews 1 (2003) CD003973
10. Coomarasamy A., Afnan M., Cheema D., van der Veen F., Bossuyt P.M., and Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod 23 (2008) 310-315
11. Al-Inany H.G., Abou-Setta A.M., Aboulghar M.A., Mansour R.T., and Serour G. Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod Biomed Online 16 (2008) 81-88
12. Tulppala M., Aho M., Tuuri T., Vilska S., Foudila T., Hakala-Ala-Pietila T., et al. Comparison of two recombinant follicle-stimulating hormone preparations in in-vitro fertilization: a randomized clinical study. Hum Reprod 14 (1999) 2709-2715
13. Brinsden P., Akagbosu F., Gibbons L.M., Lancaster S., Gourdon D., Engrand P., et al. A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization-embryo transfer. Fertil Steril 73 (2000) 114-116
14. Harlin J., Csemiczky G., Wramsby H., and Fried G. Recombinant follicle stimulating hormone in in-vitro fertilization treatment-clinical experience with follitropin alpha and follitropin beta. Hum Reprod 15 (2000) 239-244
15. Harlin J., Aanesen G., Csemiczky G., Wramsby H., and Fried G. Delivery rates following IVF treatment, using two recombinant FSH preparations for ovarian stimulation. Hum Reprod 15 (2002) 239-244
16. Robertson W.R. Gonadotrophin isoform pattern in different pharmaceutical preparations. In: Kahn J.A. (Ed). gonadotrophin isoforms facts and future. Serono Fertility Series Vol. 2 (1997), Ciconia Foundation, Copenhagen, Denmark 53-60
17. Recombinant Human FSH Product Development Group. Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility. Hum Reprod Update 4 (1998) 862-881
18. Racowsky C., Orasanu B., Hinrichsen M.J., and Ginsburg E.S. Embryo quality based on ovulation induction: defining the differences. Reprod Biomed Online 11 (2005) 22-25
19. Yang J.H., Chen H.F., Lien Y.R., Chen S.U., Ho H.N., and Yang Y.S. Elevated E2: oocyte ratio in women undergoing IVF and tubal ET. Correlation with a decrease in the implantation rate. J Reprod Med 46 (2001) 434-438